CN118126910A - Probiotic agent for improving vaginal infection and preparation method and application thereof - Google Patents
Probiotic agent for improving vaginal infection and preparation method and application thereof Download PDFInfo
- Publication number
- CN118126910A CN118126910A CN202410575027.7A CN202410575027A CN118126910A CN 118126910 A CN118126910 A CN 118126910A CN 202410575027 A CN202410575027 A CN 202410575027A CN 118126910 A CN118126910 A CN 118126910A
- Authority
- CN
- China
- Prior art keywords
- probiotic
- strain
- vaginal
- lactobacillus casei
- lactobacillus acidophilus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 59
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 59
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 53
- 206010046914 Vaginal infection Diseases 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 239000003795 chemical substances by application Substances 0.000 title claims description 7
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 23
- 244000199866 Lactobacillus casei Species 0.000 claims abstract description 23
- 238000004321 preservation Methods 0.000 claims abstract description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 21
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 18
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 18
- 238000002156 mixing Methods 0.000 claims description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- 239000004310 lactic acid Substances 0.000 claims description 9
- 235000014655 lactic acid Nutrition 0.000 claims description 9
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 7
- 229940098773 bovine serum albumin Drugs 0.000 claims description 7
- 239000002131 composite material Substances 0.000 claims description 7
- 239000008101 lactose Substances 0.000 claims description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 6
- 229920001661 Chitosan Polymers 0.000 claims description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 6
- 235000013772 propylene glycol Nutrition 0.000 claims description 6
- 239000003223 protective agent Substances 0.000 claims description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 5
- 229920002261 Corn starch Polymers 0.000 claims description 5
- 229920002125 Sokalan® Polymers 0.000 claims description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 5
- 239000011668 ascorbic acid Substances 0.000 claims description 5
- 235000010323 ascorbic acid Nutrition 0.000 claims description 5
- 229960005070 ascorbic acid Drugs 0.000 claims description 5
- 229960001631 carbomer Drugs 0.000 claims description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 5
- 239000008120 corn starch Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 5
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 5
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 4
- 239000001361 adipic acid Substances 0.000 claims description 4
- 235000011037 adipic acid Nutrition 0.000 claims description 4
- 229940072056 alginate Drugs 0.000 claims description 4
- 229920000615 alginic acid Polymers 0.000 claims description 4
- 235000010443 alginic acid Nutrition 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- 235000021355 Stearic acid Nutrition 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
- 239000008117 stearic acid Substances 0.000 claims description 3
- 239000000454 talc Substances 0.000 claims description 3
- 229910052623 talc Inorganic materials 0.000 claims description 3
- 229960000583 acetic acid Drugs 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 229960000448 lactic acid Drugs 0.000 claims description 2
- 229960004063 propylene glycol Drugs 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims 2
- 239000003826 tablet Substances 0.000 description 38
- 238000000855 fermentation Methods 0.000 description 16
- 230000004151 fermentation Effects 0.000 description 16
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 15
- 235000013958 Lactobacillus casei Nutrition 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 14
- 229940017800 lactobacillus casei Drugs 0.000 description 14
- 239000000203 mixture Substances 0.000 description 13
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 12
- 208000037009 Vaginitis bacterial Diseases 0.000 description 12
- 238000009472 formulation Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 235000010633 broth Nutrition 0.000 description 7
- 230000008961 swelling Effects 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 102000003777 Interleukin-1 beta Human genes 0.000 description 4
- 108090000193 Interleukin-1 beta Proteins 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 210000001215 vagina Anatomy 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 239000000227 bioadhesive Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000032159 Vaginal inflammation Diseases 0.000 description 2
- 201000008100 Vaginitis Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 208000027744 congestion Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 210000003905 vulva Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108010062877 Bacteriocins Proteins 0.000 description 1
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 229920001651 Cyanoacrylate Polymers 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000207201 Gardnerella vaginalis Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000010062 adhesion mechanism Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000009704 beneficial physiological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 229950002007 estradiol benzoate Drugs 0.000 description 1
- VOXZDWNPVJITMN-WKUFJEKOSA-N estradiol group Chemical group [C@@H]12CCC(O)[C@@]1(C)CC[C@@H]1C3=C(CC[C@@H]21)C=C(O)C=C3 VOXZDWNPVJITMN-WKUFJEKOSA-N 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007108 local immune response Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229940044977 vaginal tablet Drugs 0.000 description 1
- 239000000003 vaginal tablet Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to a probiotic for improving vaginal infection, and a preparation method and application thereof, wherein strains in the probiotic comprise lactobacillus casei Lactobacillus casei LC strain with a preservation number of CGMCC No.24110 and lactobacillus acidophilus Lactobacillus acidophilus LA strain with a preservation number of CCTCC No. M2022572.
Description
Technical Field
The invention belongs to the technical field of microorganisms, and relates to a probiotic agent for improving vaginal infection, and a preparation method and application thereof.
Background
Female vulvovaginal infections are now very common, which are the result of an imbalance in the vaginal ecosystem, caused by different exogenous or endogenous factors that affect the microbiota in the vagina and reduce protective lactobacilli. Lactic acid bacteria are the most abundant dominant microorganisms, 10 7~108 CFU in healthy premenopausal women's vaginal fluid, which have the function of maintaining the healthy environment of the vagina, limiting the growth of pathogenic microorganisms by producing acids, hydrogen peroxide, bacteriocins and modulating local immune responses. The most common vaginal infections are caused by pathogenic bacteria, typically gardnerella vaginalis causing Bacterial Vaginosis (BV), or fungi such as candida causing vulvovaginal candidiasis (VVC). Conventional treatment of BV is oral or intravaginal with metronidazole or clindamycin according to therapeutic guidelines, whereas VVC is typically treated locally and systemically with nystatin. Conventional therapies may produce side effects, the emergence of drug resistant strains, and recurrence of symptoms. In order to minimize these adverse effects, it is important to try to develop different alternative treatments. Therefore, the use of specific probiotic products containing lactic acid bacteria is the first choice for restoring the physiological balance of the vaginal ecosystem.
Probiotics are defined as living microorganisms that, if administered in sufficient amounts, have a beneficial physiological effect on the host. The beneficial effects of lactic acid bacterial strains on BV and VVC have been reported in historical studies, and probiotic formulations have been tested orally and topically so far, however the intravaginal route of administration has so far appeared to be the first choice for probiotic management. Its advantages are: reduces the severity of gastrointestinal enzyme and acid effects, and overcomes pain and tissue damage caused by other parenteral routes. These advantages are mainly manifested in that the patient is given a lower dose, and less frequent administration results in a high absorption rate of the probiotic bacteria, which is not affected by the gastrointestinal tract. Formulation studies that colonize the vaginal environment and maintain relative viability are new challenges.
Disclosure of Invention
Aiming at the defects of the prior art, the invention aims to provide a probiotic agent for improving vaginal infection, and a preparation method and application thereof.
In order to achieve the aim of the invention, the invention adopts the following technical scheme:
In a first aspect, the invention provides a probiotic for improving vaginal infection, wherein strains in the probiotic comprise lactobacillus casei Lactobacillus casei LC strain with a preservation number of CGMCC No.24110 and lactobacillus acidophilus Lactobacillus acidophilus LA strain with a preservation number of CCTCC No. M2022572.
The invention creatively discovers that the related combination of lactobacillus casei LC16 strain and lactobacillus acidophilus LA18 strain can significantly improve the vulvar tract infection, and the effect is larger than that of single strain application. The specific expression is as follows: (1) effective inhibition of pathogenic bacteria growth; (2) a reduction in the inflammatory response of the mouse vulva tract; (3) Reduces the serum inflammatory factors IL-1 beta, TNF-alpha and IL-6 level of BV mice.
Preferably, the ratio of the viable count of the Lactobacillus casei Lactobacillus casei LC strain to the Lactobacillus acidophilus Lactobacillus acidophilus LA strain is (3-9): 1.
Wherein, the specific point values in (3-9) can be selected from 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, etc., and other specific point values in the above numerical range can be selected, and will not be described in detail herein.
Preferably, the viable count of the lactobacillus casei Lactobacillus casei LC strain and the lactobacillus acidophilus Lactobacillus acidophilus LA strain is independently not lower than 1×10 9 CFU/mL, such as 1×109CFU/mL、2×109 CFU/mL、3×109 CFU/mL、4×109 CFU/mL、5×109 CFU/mL、6×109 CFU/mL、7×109 CFU/mL、8×109 CFU/mL、9×109 CFU/mL、1×1010 CFU/mL、2×1010 CFU/mL、5×1010CFU/mL、8×1010 CFU/mL、1×1011 CFU/mL、1×1012 CFU/mL、1×1013 CFU/mL, and other specific values in the above numerical range are selected, and will not be described in detail herein.
Preferably, the dosage form of the probiotic comprises a tablet.
Preferably, the probiotic agent further comprises a protective agent, a quick release component and a slow release component.
Preferably, the protective agent comprises any one or a combination of at least two of acetic acid, bovine serum albumin, propylene glycol, lactic acid or alginate.
Preferably, the probiotics comprises 0.1-1% of acetic acid, 0.1-0.5% of bovine serum albumin, 0.1-0.4% of propylene glycol and 0.1-1% of lactic acid by mass percent.
The mass percentage of the acetic acid may be selected from 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, etc., the mass percentage of the bovine serum albumin may be selected from 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, etc., the mass percentage of the propylene glycol may be selected from 0.1%, 0.2%, 0.3%, 0.4%, etc., and the mass percentage of the lactic acid may be selected from 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, etc., and other specific values in the above numerical ranges may be selected, and will not be repeated here.
Preferably, the retarded release component comprises any one or a combination of at least two of stearic acid, sodium carboxymethyl cellulose, ascorbic acid, lactose, talc, magnesium stearate, chitosan or carbomer.
Preferably, the quick release component comprises any one or a combination of at least two of lactose, adipic acid, sodium bicarbonate or corn starch.
In a second aspect, the present invention provides a method of preparing a probiotic for ameliorating vaginal infections according to the first aspect, the method comprising:
(1) Mixing the activated and fermented strain with a protective agent, and freeze-drying to obtain composite probiotic particles;
(2) Mixing the composite probiotic granule with the slow release component, granulating, mixing with the quick release component, and tabletting.
In a third aspect, the present invention provides the use of a probiotic for the amelioration of a vaginal infection according to the first aspect in the manufacture of a product for the amelioration of a vaginal infection.
Compared with the prior art, the invention has the following beneficial effects:
The invention creatively discovers that the related combination of lactobacillus casei LC16 strain and lactobacillus acidophilus LA18 strain can significantly improve the vulvar tract infection, and the effect is larger than that of single strain application. The specific expression is as follows: (1) effective inhibition of pathogenic bacteria growth; (2) a reduction in the inflammatory response of the mouse vulva tract; (3) Reduces the serum inflammatory factors IL-1 beta, TNF-alpha and IL-6 level of BV mice.
Drawings
Figure 1 is a graph of the probiotic tablet swelling index over 24 hours.
FIG. 2 shows the results of bacterial viability tests in different environments.
Detailed Description
The technical scheme of the invention is further described by the following specific embodiments. It will be apparent to those skilled in the art that the examples are merely to aid in understanding the invention and are not to be construed as a specific limitation thereof.
The Lactobacillus casei Lactobacillus casei LC strain related in the following is classified and named as Lactobacillus casei Lactobacillus casei, the preservation number is CGMCC No.24110, the preservation date is 2021, 12 and 15, the preservation unit is China general microbiological culture Collection center, and the preservation address is North Star Xila No.1 and 3 in the Korean region of Beijing city.
Lactobacillus acidophilus Lactobacillus acidophilus LA strain related in the following is classified and named Lactobacillus acidophilus LA, the preservation number is CCTCC NO: M2022572, the preservation date is 2022, 05 and 09, the preservation unit is China center for type culture Collection, and the preservation address is China, university of Wuhan.
Alginate, corn starch, ascorbic acid, stearic acid, sodium carboxymethylcellulose, ascorbic acid, lactose, talc, magnesium stearate, chitosan, adipic acid, sodium bicarbonate were all purchased from the Ming Xin chemical plant.
Acetic acid, and bovine serum albumin, propylene glycol, lactic acid were all purchased from Sigma.
Example 1
The embodiment provides a composite probiotic fermentation liquor, wherein the ratio of the viable count of lactobacillus casei LC16 strain to lactobacillus acidophilus LA18 strain in the fermentation liquor is 4:1, and the total viable count is 1X 10 9 CFU/mL.
The preparation method comprises the following steps:
inoculating Lactobacillus casei LC16 strain and Lactobacillus acidophilus LA18 strain into MRS culture medium, culturing at 37deg.C for 24h, adjusting viable count with sterile physiological saline, and mixing.
Example 2
The embodiment provides a composite probiotic fermentation liquor, wherein the ratio of the viable count of lactobacillus casei LC16 strain to lactobacillus acidophilus LA18 strain in the fermentation liquor is 1:1, and the total viable count is 1X 10 9 CFU/mL.
The preparation method is described in example 1.
Example 3
The embodiment provides a composite probiotic fermentation liquor, wherein the ratio of the viable count of lactobacillus casei LC16 strain to lactobacillus acidophilus LA18 strain in the fermentation liquor is 10:1, and the total viable count is 1X 10 9 CFU/mL.
The preparation method is described in example 1.
Comparative example 1
This comparative example provides a complex probiotic fermented liquor differing from example 1 only in that the lactobacillus casei LC16 strain was replaced with lactobacillus casei ATCC393 strain, the ratio of viable count of lactobacillus casei to lactobacillus acidophilus and total viable count were kept unchanged.
The preparation method is described in example 1.
Comparative example 2
This comparative example provides a complex probiotic fermented liquid differing from example 1 only in that lactobacillus acidophilus LA18 strain was replaced with lactobacillus acidophilus ATCC4356 strain, and the ratio of the viable count of lactobacillus casei to lactobacillus acidophilus and the total viable count were kept unchanged.
The preparation method is described in example 1.
Comparative example 3
The comparative preparation example provides a probiotic fermentation broth, wherein the viable count of the Lactobacillus casei LC16 strain in the fermentation broth is 1X 10 9 CFU/mL.
The preparation method is described in example 1.
Comparative example 4
The comparative preparation example provides a probiotic fermentation broth, and the viable count of Lactobacillus acidophilus LA18 strain in the fermentation broth is 1×10 9 CFU/mL.
The preparation method is described in example 1.
Test example 1
Influence of in vitro probiotic bacterial liquid on Escherichia coli
The E.coli standard strain (ATCC 25922) was inoculated into LB liquid medium, cultured at 37℃for 18 hours, centrifuged (3000 rpm,5 min) to collect the bacteria, and diluted 10-fold with PBS to prepare a desired bacterial suspension. Coli density was 10 4 CFU/mL.
1ML of 2 XPTY liquid medium was added to each well of a 24-well microplate, and 500. Mu.L of the E.coli suspension prepared as described above was inoculated. Then 500. Mu.L of the fermentation broths described in examples 1-3 and comparative examples 1-4, respectively, were added as experimental groups, and 500. Mu.L of physiological saline was used as a growth control. As a blank, 1mL of 2 XPTY liquid medium and 1mL of sterile physiological saline were additionally used. All experiments were performed in triplicate to ensure reproducibility. After anaerobic culture at 37℃for 48 hours, the number of viable E.coli cells was measured by plate counting, and the results are shown in Table 1.
TABLE 1
The in vitro experiment result shows that lactobacillus casei LC16 and lactobacillus acidophilus LA18 fermentation liquid have different degrees of inhibition effects on the growth of escherichia coli, and the LC16 and the LA18 can be matched with each other in the effect, and the combined use effect of the two is superior to that of the single use of the two strains.
Test example 2
BV model mouse model establishment and animal grouping and treatment
88 Female ICR mice were weighed and randomly divided into 11 groups (n=8), namely normal, estrogenic, model, antibiotic control (kanamycin 7 mg/kg daily for 6 days), probiotic (vaginal infusion 1mL daily for 6 days of fermentation broth treatment as described in examples 1-3 and comparative examples 1-4). Except for the normal group, the mice were subcutaneously injected with estrogen (estradiol benzoate) (0.1 mg/mouse) in the lower abdomen 3 days before the bacteria were inoculated in the vagina, and then 30 μl (10 8 CFU/mL) of an escherichia coli suspension was intravaginally injected into the mice of the model group, the antibiotic control group and the probiotic group each day, and BV models were established in succession of 5D.
The 3 clinical indexes of vaginal congestion, edema and hemorrhage of the mice are respectively scored: no congestion, edema, hemorrhage, infiltration of 0 minutes; a score of 0.1 with a slight effect; an effect of 0.2 points; severe 0.3 minutes; extremely severe 0.4 minutes. The severity of the inflammation and the therapeutic effect were then quantitatively analyzed.
TABLE 2
The results of relieving clinical symptoms of BV are shown in Table 1, and each clinical index of the mice in the normal group is in the normal range. The clinical symptoms of BV such as vaginal inflammation, mucosal congestion, secretion turbidity and the like of the mice in the model group are more obvious than those of the mice in other groups, and the clinical index score is increased than that of the mice in other groups. Chronic mild redness occurred in the vaginal opening of the estradiol group mice. After treatment of 3d, the vaginal redness and swelling and the secretion turbidity of the antibiotic group and the probiotic group are obviously improved. The lactobacillus casei LC16 and lactobacillus acidophilus LA18 fermentation liquid has a certain improvement effect on vaginal inflammation and secretion turbidity, and the two strains can be matched with each other in the effect.
Test example 3
The mice described in test example 2 were sacrificed after the end of the treatment and blood samples were collected. Serum is collected after centrifugation and detected by a double-antibody sandwich ABC-ELISA method according to ELISA kit instructions. The therapeutic effect of the antibiotic and probiotic bacterial suspensions was evaluated by detecting the expression levels of the inflammatory factors IL-1 beta, TNF-alpha and IL-6, and the results are shown in Table 3 without comparison in the B-group model set-up control group.
TABLE 3 Table 3
The colpitis caused by colibacillus has inhibiting effect on the expression of serum inflammatory factors IL-1 beta, TNF-alpha and IL-6 of BV mice, and the treatment effect of the group of the example 1 is superior to that of the antibiotics group and other groups. The combined use of lactobacillus casei LC16 and lactobacillus acidophilus LA18 fermentation liquid proves that the inflammatory reaction of BV mice can be reduced, and the two strains can be matched with each other in the effect.
Test example 4
Freeze-dried probiotic particles: mixing the fermentation broth obtained in example 1 with 0.5% acetic acid, 0.3% bovine serum albumin, 0.2% propylene glycol and 0.5% lactic acid to form granules, mixing with 1% alginate, emulsifying, and freeze drying.
A particulate substrate: 2% corn starch was prepared as a 10% paste for wetting the pellet mixture, and 2% sodium bicarbonate, 10% adipic acid, 10% corn starch and the balance lactose were added. The pellets were dried through a 40 mesh screen in an oven at 37 c until the weight was constant and after drying the pellets the agglomerates were removed through a 20 mesh screen.
The lyophilized probiotic particles and the granular matrix were then formulated into tablets in the proportions shown in table 4.
TABLE 4 Table 4
The preparation method comprises the following steps:
mixing the freeze-dried probiotic particles with ascorbic acid, lactose, sodium carboxymethyl cellulose, carbomer, chitosan, talcum powder, magnesium stearate and sodium bicarbonate, and granulating;
mixing the product obtained in the step (2) with a granular substrate, drying, and tabletting.
1. Tablet swelling index study
The preparation method of the simulated vaginal fluid comprises the following steps: 3.5 g/L NaCl, 1.4 g/L KOH, 0.2 g/L Ca (OH) 2, 2.0 g/L lactic acid, 1.0 g/L acetic acid, 0.2 g/L glycerol, 0.4 g/L urea, 5.0 g/L glucose, 0.02 g/L bovine serum albumin (all available from Shanghai, biotechnology Co., ltd.) the mixture was adjusted to pH 5.5.
The tablets were weighed (G1) and placed in a pre-weighed 200 mesh pore size stainless steel basket. The tablet-containing mesh was immersed in 25 mL simulated vaginal fluid in a glass beaker at 37 ℃ to expand the tablet. The stainless steel basket was removed from the beaker, and after removing excess water with filter paper, it was re-weighed (G2) at a predetermined time. The experiment was performed in three times and the final data of the swelling index (%) was calculated as follows:
As a result, as shown in fig. 1, it is necessary to conduct hydration studies to understand the swelling capacity of the tablet, which is directly related to the adhesion mechanism, because of the presence of the expandable bioadhesive polymer in the formulation, the stronger the swelling capacity, the better the tablet adhesion. The swelling index study proves that two different release curves, one is rapid bacterial release of the effervescent layer and the other is prolonged release of the slow-release matrix layer until the end of 24 hours, indicate that in the probiotic tablet for improving vaginal infection, the slow-release layer tablet swells and decreases due to small carbomer and chitosan addition amount in the formula tablet A after the proper blending proportion of sodium carboxymethyl cellulose is changed, and the slow-release layer tablet swells and increases when the carbomer and chitosan addition amount in the formula tablet B is relatively more.
2. Tablet adhesion study
New Zealand female white rabbits with dead weights greater than 2.5kg were euthanized, the vaginal tissue exposed at 2cm×2cm was dissected, washed with phosphate buffer (PBS, pH 6.8), and the mucosa integrity was maintained. The formulation B of the above experiment was selected and 2 drops of cyanoacrylate glue were added dropwise to the tablets, which were attached to a dynamometer support. The vaginal tissue was kept moist by washing with PBS solution, and then the free side of the tablet was moistened with simulated vaginal fluid, with the fingertip forced to bring its matrix layer into contact with the vaginal tissue mucosal surface for 20s. After 2 minutes the tablet forms an adhesion with the tissue. The adhesion strength of the tablets (the force required to detach the tablets from the rabbit vaginal mucosa) was measured using a dynamometer. The bioadhesive strength of the vaginal tablet was measured by a load cell in grams (g).
Adhesion (N) =bioadhesive strength (g) ×0.0098
The 4 formulation tablet adhesion test was 3 times, 3 tablets were randomly drawn each time for study.
The adhesion and adhesion time results are shown in Table 5.
TABLE 5
The adhesion of the tablet is very important, and the main function is to enable probiotics to be attached to the administration place for a long time and prevent the probiotics from being discharged without reaching the action effect. As the results in table 5 show, the results of the adhesion strength and adhesion are expressed as the average of three tablet measurements per completion of the test (x represents p < 0.05). To check whether the adhesion achieved guarantees a sustained tablet in the vagina until the probiotic load is completely released, it can be seen from table 5 that the adhesion test results for each tablet studied are similar. Formulation C had the lowest tablet adhesion, which may be related to the vaginal mucosa condition used, since in this case its surface was more even and smooth, formulation B had the highest tablet adhesion of 0.0983N. Formulation B tablets were selected for subsequent study.
The test also investigated the adhesion time, and the results of the analysis of the tablets of 4 different formulations were expressed as the time average of the measurements of the number of adhesion hours tested for each formulation. The adhesion time average was 12.75.+ -. 0.42 h. The results indicate that probiotic tablets to ameliorate vaginal infections can be administered 2 times daily.
3. Tablet probiotic storage and vitality test study
Group B probiotic formula tablets, 10 tablets each, were stored in a room temperature environment and in a closed desiccator for 60 days, respectively. The tablets were moisture protected in a closed desiccator using silica gel as the desiccant. During this time, the microorganisms in the tablets were cultured every 30 days to evaluate the viability of the bacteria. Specifically, the tablets were dissolved in 9mL of sterile purified water, 1mL was aspirated onto MRS solid medium at 37℃and incubated for 48h for plate counting.
The results are shown in FIG. 2, and the bacterial activity was measured after 60 days of storage at room temperature in a dry box. n=10, all points are expressed as mean±sd, stability studies indicate that formulation B tablet bacterial viability remains unchanged overall for 60 days at desiccator and room temperature.
The applicant states that the present invention is illustrated by the above examples as a probiotic agent for the amelioration of vaginal infections, and its preparation and use, but the invention is not limited to, i.e. it is not meant that the invention must be practiced in dependence upon the above examples. It should be apparent to those skilled in the art that any modification of the present invention, equivalent substitution of raw materials for the product of the present invention, addition of auxiliary components, selection of specific modes, etc., falls within the scope of the present invention and the scope of disclosure.
The preferred embodiments of the present invention have been described in detail above, but the present invention is not limited to the specific details of the above embodiments, and various simple modifications can be made to the technical solution of the present invention within the scope of the technical concept of the present invention, and all the simple modifications belong to the protection scope of the present invention.
In addition, the specific features described in the above embodiments may be combined in any suitable manner, and in order to avoid unnecessary repetition, various possible combinations are not described further.
Claims (10)
1. The probiotics for improving vaginal infection is characterized in that strains in the probiotics comprise lactobacillus casei Lactobacillus casei LC strain with a preservation number of CGMCC No.24110 and lactobacillus acidophilus Lactobacillus acidophilus LA strain with a preservation number of CCTCC No. M2022572.
2. The probiotic for improving vaginal infection according to claim 1, wherein the ratio of viable count of lactobacillus casei Lactobacillus casei LC strain and lactobacillus acidophilus Lactobacillus acidophilus LA strain is (3-9): 1.
3. The probiotic for improving vaginal infection according to claim 1, wherein the viable count of lactobacillus casei Lactobacillus casei LC strain and lactobacillus acidophilus Lactobacillus acidophilus LA strain is not lower than 1 x 10 9 CFU/mL independently.
4. The probiotic for ameliorating vaginal infections of claim 1, wherein the dosage form of the probiotic comprises a tablet.
5. A probiotic for ameliorating a vaginal infection according to claim 1, wherein said probiotic further comprises a protective agent, a quick release component and a slow release component.
6. The probiotic agent for improving vaginal infections according to claim 5, characterized in that said protective agent comprises any one or a combination of at least two of acetic acid, bovine serum albumin, propylene glycol, lactic acid or alginate.
7. A probiotic for ameliorating a vaginal infection according to claim 5, wherein said retarded release ingredients comprise any one or a combination of at least two of stearic acid, sodium carboxymethylcellulose, ascorbic acid, lactose, talc, magnesium stearate, chitosan or carbomer.
8. The probiotic for ameliorating vaginal infections according to claim 5, wherein said quick-release ingredients comprise any one or a combination of at least two of lactose, adipic acid, sodium bicarbonate or corn starch.
9. A method of preparing a probiotic for ameliorating vaginal infections according to any of claims 1-8, characterized in that the method of preparation comprises:
(1) Mixing the activated and fermented strain with a protective agent, and freeze-drying to obtain composite probiotic particles;
(2) Mixing the composite probiotic granule with the slow release component, granulating, mixing with the quick release component, and tabletting.
10. Use of a probiotic according to any one of claims 1-8 for the preparation of a product for ameliorating vaginal infections.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410575027.7A CN118126910B (en) | 2024-05-10 | 2024-05-10 | Probiotic agent for improving vaginal infection and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410575027.7A CN118126910B (en) | 2024-05-10 | 2024-05-10 | Probiotic agent for improving vaginal infection and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN118126910A true CN118126910A (en) | 2024-06-04 |
CN118126910B CN118126910B (en) | 2024-07-02 |
Family
ID=91239357
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202410575027.7A Active CN118126910B (en) | 2024-05-10 | 2024-05-10 | Probiotic agent for improving vaginal infection and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN118126910B (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140234259A1 (en) * | 2012-12-11 | 2014-08-21 | Suzanah Juras | Natural Intra-Vaginal Inserts to Control Imbalanced pH |
CN114634901A (en) * | 2022-05-18 | 2022-06-17 | 微康益生菌(苏州)股份有限公司 | Lactobacillus casei LC16 for promoting bone health and culture method and application thereof |
CN114990030A (en) * | 2022-07-18 | 2022-09-02 | 微康益生菌(苏州)股份有限公司 | Lactobacillus acidophilus LA18 and application thereof in preparing product for regulating intestinal flora or immunoregulation |
CN115768452A (en) * | 2020-04-28 | 2023-03-07 | 伊比利亚护理健康有限公司 | Coriolus versicolor extract for treating vaginal or cervical disorders caused by infectious pathogens |
-
2024
- 2024-05-10 CN CN202410575027.7A patent/CN118126910B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140234259A1 (en) * | 2012-12-11 | 2014-08-21 | Suzanah Juras | Natural Intra-Vaginal Inserts to Control Imbalanced pH |
CN115768452A (en) * | 2020-04-28 | 2023-03-07 | 伊比利亚护理健康有限公司 | Coriolus versicolor extract for treating vaginal or cervical disorders caused by infectious pathogens |
CN114634901A (en) * | 2022-05-18 | 2022-06-17 | 微康益生菌(苏州)股份有限公司 | Lactobacillus casei LC16 for promoting bone health and culture method and application thereof |
CN114990030A (en) * | 2022-07-18 | 2022-09-02 | 微康益生菌(苏州)股份有限公司 | Lactobacillus acidophilus LA18 and application thereof in preparing product for regulating intestinal flora or immunoregulation |
Also Published As
Publication number | Publication date |
---|---|
CN118126910B (en) | 2024-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110016442B (en) | Application of lactobacillus rhamnosus and compound bacterium powder thereof in product for preventing and treating vaginitis | |
EP2158916A1 (en) | Administration unit comprising lactic acid bacteria | |
CN108004187A (en) | A kind of lactobacillus gasseri and its application for being used to prepare vagina antibacterial medicines | |
JPS60501160A (en) | vaginal capsule | |
JPH11504049A (en) | Compositions for genitourinary and intestinal disorders, comprising substances from plant species of the azalea family and lactic acid bacterial growth factor | |
KR20160067893A (en) | Lactobacillus crispatus and application thereof | |
JPH11504048A (en) | Genitourinary and intestinal compositions | |
CN116200306B (en) | Lactobacillus rhamnosus LRa16, and application and product thereof in preparation of medicines for treating genital tract infection | |
CN110448577B (en) | Probiotic microcapsule preparation for repairing ulcerative colitis | |
CN102727531A (en) | Active lactic acid bacteria capsules with treatment and prevention effect on vaginitis | |
CN110917174A (en) | Oral probiotic capsule for regulating balance of female vaginal flora and preparation method thereof | |
CN111084831A (en) | Bacteriostatic composition for inhibiting vaginal pathogenic bacteria and application thereof | |
CN105920659A (en) | Bacteriostatic hydrogel dressing for wound repair and preparation method thereof | |
CN108403725A (en) | Composition for treating digestive tract ulcer and its application | |
CN118126910B (en) | Probiotic agent for improving vaginal infection and preparation method and application thereof | |
US20110135615A1 (en) | Transiently buffered lactobacillus preparations and use thereof | |
CN111567807A (en) | Rhamnose-containing lactobacillus composition for inhibiting inflammatory reaction and resisting vaginitis and application thereof | |
WO2023066163A1 (en) | Exopolysaccharide separated from lactobacillus delbrueckii and streptococcus thermophilus fermented yoghourt and application thereof | |
CN112057601B (en) | Preparation method of active probiotic freeze-dried powder and application of active probiotic freeze-dried powder in skin and gynecological diseases | |
CN112501051B (en) | Probiotic composite preparation and application thereof in vaginal flora regulation and HPV resistance | |
CN115404185A (en) | Lactobacillus crispatus LCP051 for antagonizing candida albicans and application thereof | |
CN115590893A (en) | Compound probiotic composition capable of inhibiting helicobacter pylori and application thereof | |
CN111406928B (en) | Red date fermented food with function of improving chronic diarrhea and preparation method and application thereof | |
CN118086152B (en) | Composite probiotics for improving bacterial vaginitis, probiotics preparation and application thereof | |
CN107320440B (en) | Sulforaphane-containing gastric retention composition and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant |